Acadia Pharmaceuticals | ACAD - Sales Revenues


Acadia Pharmaceuticals reported $307.96M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
ALKERMES USD 496.01M 103.1M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 256.15M 91.25M Jun/2026
Cytokinetics USD 28.6M 9.25M Jun/2026
Eisai JPY 234.33B 28.9B Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Incyte USD 1.67B 400M Jun/2026
J&J USD 25.4B 89M Sep/2026
Moderna USD 100M 289M Jun/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Prothena USD 51.08M 51.06M Mar/2026
PTC Therapeutics USD 361M 88M Jun/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026